Terry Heiman-Patterson, MD, Director of the Temple MDA/ALS Center of Hope, offered insight to the Associated Press for an article about NurOwn, a stem cell-based therapy for patients with ALS, or amyotrophic lateral sclerosis. At the time, the treatment was awaiting approval by the U.S. Food and Drug Administration (FDA). The FDA eventually voted against the therapy.
Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.
Learn More
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH